Adjuvance Technologies, Inc.
Products
Saponex Adjuvant Product Line
Saponex is Adjuvance’s synthetic version of naturally occurring QS-21, the world’s leading adjuvant candidate. QS-21 is a naturally occurring saponin adjuvant isolated from the bark of a South American tree. Unlike the natural product, Saponex contains the two molecules responsible for QS-21’s immunostimulatory activity (QS-21-apiose and QS-21-xylose) in high purity. Although the ratio of apiose:xylose in the natural product is approximately 65:35, Saponex’s synthetic technology allows Adjuvance to provide the two molecules separately or combined in any ratio desired. Saponex is a custom tailored solution to your saponin-adjuvant needs. Adjuvance’s Saponex product line consists of Saponex-H, Saponex-A and Saponex-X. Although all three products utilize the same underlying technology, Saponex-H provides heterogeneously comprised QS-21-apiose and QS-21-xylose in the same ratio as found in the natural product. Because we synthesize these molecules separately, we are also able to control the isomeric ratios, varying the molecular constituency to suit your needs. It is this key aspect of TriSST that enables Adjuvance to provide you with each QS-21 isomer separately with either Saponex-A (QS-21-apiose) or Saponex-X (QS-21-xylose).
Saponex-H
Heterogeneous saponin adjuvant mixture,comprised of highly pure synthetic QS-21-apiose and synthetic QS-21–xylose.
Saponex-A
Homogeneous saponin adjuvant comprised of highly pure synthetic QS-21-apiose.
Saponex-X
Homogeneous saponin adjuvant comprised of highly pure synthetic QS-21-xylose.
TiterQuil Adjuvant Product Line
In addition to providing quality, efficiency, and efficacy to QS-21 production, TriSST enables adaptability via rationally designed structural variants. Making very simple modifications to one portion (or more) of the molecule provides an infinite number of possibilities for unique TiterQuil molecules. For example, naturally occurring QS-21 breaks down realatively quickly at physiologic conditions because of two unstable ester linkages within the acyl chain.
With the first generation of our technology (TiterQuil 101, 102 & 103), we have systematically improved natural QS-21 and strategically replaced these labile esters, vastly improving stability during storage and under physiologic conditions.
TriSST represents a viable solution to the dearth of acceptable vaccine adjuvants. TriSST is the most reliable method of producing the world’s leading adjuvant candidate and is capable of providing an entire portfolio of novel adjuvant molecules with improving stability, toxicity, efficacy and cost profiles. In our first generation of novel TiterQuil adjuvants we have already improved the toxicity, stability, cost and efficacy profile of QS-21.